XOMA Corporation (XOMA)
| Previous close | 23.69 |
| Open | 24.28 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 24.28 - 24.59 |
| 52-week range | 13.48 - 27.00 |
| Volume | |
| Avg. volume | 17,540 |
| Market cap | 284.708M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.04 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | 2.16 (8.91%) |
| Ex-dividend date | 02 Apr 2024 |
| 1y target est | 57.00 |
GlobeNewswireXOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA’s balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well
ZacksCertara, Inc. (CERT) Q1 Earnings Meet Estimates
Certara (CERT) delivered earnings and revenue surprises of 0% and 2.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ZacksXoma (XOMA) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
